Haleos Labs Limited vs Venus Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Haleos Labs Limited is ₹ 1600 as of 18 May 15:30 . The P/E Ratio of Haleos Labs Limited changed from 11 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 8.05% over 5 yearsThe P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2021 to 8.8 on March 2025 . This represents a CAGR of 9.86% over 5 years The Market Cap of Haleos Labs Limited changed from ₹ 149.61 crore on March 2021 to ₹ 326.64 crore on March 2025 . This represents a CAGR of 16.90% over 5 yearsThe Market Cap of Venus Remedies Ltd changed from ₹ 338.91 crore on March 2021 to ₹ 400.47 crore on March 2025 . This represents a CAGR of 3.39% over 5 years The revenue of Haleos Labs Limited for the Dec '25 is ₹ 94.97 crore as compare to the Sep '25 revenue of ₹ 81.79 crore. This represent the growth of 16.11% The revenue of Venus Remedies Ltd for the Dec '25 is ₹ 182.78 crore as compare to the Sep '25 revenue of ₹ 194.46 crore. This represent the decline of -6.01% The ebitda of Haleos Labs Limited for the Dec '25 is ₹ 14.23 crore as compare to the Sep '25 ebitda of ₹ 13.99 crore. This represent the growth of 1.72% The ebitda of Venus Remedies Ltd for the Dec '25 is ₹ 40.04 crore as compare to the Sep '25 ebitda of ₹ 32.67 crore. This represent the growth of 22.56% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 6.65 crore over 7 quarters. This represents a CAGR of -3.67% The net profit of Venus Remedies Ltd changed from ₹ 1.22 crore to ₹ 25.58 crore over 7 quarters. This represents a CAGR of 469.07% The Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 yearsThe Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

About Venus Remedies Ltd

Incorporated in 1989 Venus Remedies Limited, formerly known as Venus Glucose Pvt Ltd, was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited.
The Company was promoted and managed by Chaudhary & Family.
The Company is one of the handful player in pharmaceutical sector to launch injectables globally.
It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). At present, Venus focuses on specialized therapeutic areas including anti-infectives (antibiotics), oncology, neurology, pain management, and skin and wound care.
In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana.

FAQs for the comparison of Haleos Labs Limited and Venus Remedies Ltd

Which company has a larger market capitalization, Haleos Labs Limited or Venus Remedies Ltd?

Market cap of Haleos Labs Limited is 483 Cr while Market cap of Venus Remedies Ltd is 1,281 Cr

What are the key factors driving the stock performance of Haleos Labs Limited and Venus Remedies Ltd?

The stock performance of Haleos Labs Limited and Venus Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Haleos Labs Limited and Venus Remedies Ltd?

As of May 18, 2026, the Haleos Labs Limited stock price is INR ₹1600.0. On the other hand, Venus Remedies Ltd stock price is INR ₹958.7.

How do dividend payouts of Haleos Labs Limited and Venus Remedies Ltd compare?

To compare the dividend payouts of Haleos Labs Limited and Venus Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.